Tirzepatide

Tirzepatide (Brand names: Mounjaro® for Type 2 Diabetes; Zepbound® for Chronic Weight Management) is a first-in-class, dual agonist (or “twincretin”) targeting both the GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. It is a once-weekly subcutaneous injection that offers superior efficacy in glycemic control and provides unprecedented levels of weight loss in clinical trials compared to earlier single-agonist drugs.